Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated polio vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Trivalent inactivated polio vaccine (IPV) is a sterile suspension containing three strains of poliovirus—Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett)—that are grown in Vero cell cultures and then inactivated with formaldehyde. The vaccine is administered by intramuscular or subcutaneous injection. It induces IgG-mediated immunity, preventing the progression of poliovirus infection to viremia and protecting motor neurons from damage, thereby eliminating the risk of paralytic polio. Each dose contains defined D-antigen units for each serotype and may include trace amounts of antibiotics used during production as well as preservatives such as 2-phenoxyethanol[4][7][9]. The primary indication is the prevention of poliomyelitis.
- Brand names
- IPOL
- Other names
- IPVinactivated poliomyelitis vaccinetrivalent IPV
02
Targets
Poliovirus capsid surface epitopes
Beyond the preview
Go deeper on trivalent inactivated polio vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated polio vaccine.